Coya Therapeutics, Inc. is starting a new phase of its ALSTARS Trial for COYA 302.

Oct 14, 2026, 10:04 AM ETTrialRead the original at SEC EDGAR

Neutral

Coya plans to extend its ALS study, which may add longer-term safety and treatment data, but has moved its planned FTD study to 2027. With no new results on COYA 302, these changes leave the company's outlook unchanged.

COYA · Coya Therapeutics, Inc.

AI read · Neutral

The AI's read

The longer study may collect more information about treatment and safety. Coya is also shifting resources to ALS, which delays its planned FTD study. The report gives no new results showing whether COYA 302 helps patients, so the changes do not point clearly in one direction.

Get alerts for COYA

Follow Coya Therapeutics, Inc. (COYA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for COYA

Free on the App Store and Google Play, or on the web.